# OnCo record keynote-426 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/keynote-426/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "keynote-426", "NCT02853331" ;
  schema:name "KEYNOTE-426"@en ;
  schema:description "The first immunotherapy plus targeted-pill combination for kidney cancer, improving survival across all risk groups."@en ;
  schema:url <https://onco.cc/trials/keynote-426/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02853331> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2016-09-16" ;
  onco:cancers <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/clear-cell-rcc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/axitinib/>, <https://onco.cc/drugs/sunitinib/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:people <https://onco.cc/people/thomas-powles/>, <https://onco.cc/people/brian-rini/>, <https://onco.cc/people/lee-jae-lyun/> .